{"id":959,"date":"2026-04-20T14:26:19","date_gmt":"2026-04-20T18:26:19","guid":{"rendered":"https:\/\/www.apslaw.com\/its-your-business\/?p=959"},"modified":"2026-04-20T14:26:21","modified_gmt":"2026-04-20T18:26:21","slug":"ai-patent-strategy-and-what-actually-drives-outcomes-in-2026-part-1","status":"publish","type":"post","link":"https:\/\/www.apslaw.com\/its-your-business\/2026\/04\/20\/ai-patent-strategy-and-what-actually-drives-outcomes-in-2026-part-1\/","title":{"rendered":"AI, Patent Strategy, and What Actually Drives Outcomes in 2026 – Part 1"},"content":{"rendered":"\n

Part 1: Due Diligence and Opinions<\/strong><\/p>\n\n\n\n

This is the first article in a four-part series examining how AI is reshaping patent strategy across the lifecycle of life sciences assets\u2014from diligence and prosecution to transactions and litigation\u2014and where human judgment continues to drive outcomes.<\/p>\n\n\n\n

AI Is Now Standard in Patent Diligence<\/h3>\n\n\n\n

By 2026, AI-driven tools are embedded in virtually every serious patent diligence workflow.  Investors, acquirers, and corporate development teams routinely deploy these tools to analyze prior art landscapes, map claim scope against products and competitors, and identify risks under 35 U.S.C. \u00a7\u00a7102, 103, and 112, as well as potential freedom-to-operate impediments.  What once required weeks of associate time and outside counsel review\u2014manually parsing prosecution histories, mapping claim elements to product features, and cross-referencing prior art\u2014can now be completed in hours.<\/p>\n\n\n\n

But that acceleration has not simplified diligence.  It has shifted where the real decisions are made.  The bottleneck is no longer information gathering; it is interpretation.  And interpretation is where the gap between a competent diligence exercise and a genuinely valuable one has widened.<\/p>\n\n\n\n

The First Layer Is No Longer the Differentiator<\/h3>\n\n\n\n

AI has effectively standardized the first layer of patent diligence\u2014issue spotting.  In many transactions today, both sides are working from substantially similar datasets and reaching similar initial observations.  The same prior art references are flagged.  The same potential \u00a7112 written description gaps surface.  The same clusters of continuation patents are mapped.<\/p>\n\n\n\n

This is a fundamental shift.  A decade ago, the quality of a diligence exercise often turned on whether the team even identified the right issues.  A skilled practitioner who spotted a lurking enablement problem or recognized that a key prior art reference had been mischaracterized during prosecution could change the trajectory of a deal.  That kind of issue spotting, while still important, is increasingly commoditized.  AI tools are quite good at surfacing these issues, and they do so consistently.<\/p>\n\n\n\n

The differentiator is no longer what issues are identified\u2014it is how those issues are interpreted and what can be done about them.  Two diligence teams can start with the same AI-generated risk report and arrive at fundamentally different conclusions about portfolio value, deal structure, and strategic posture.  The divergence happens in the analysis layer\u2014the layer that requires legal judgment, technical fluency, and commercial awareness that AI does not supply.<\/p>\n\n\n\n

Where Judgment Diverges: Three Scenarios<\/h3>\n\n\n\n

The following scenarios illustrate how identical AI outputs can lead to materially different conclusions depending on the depth of analysis and judgment applied.  These are composites drawn from common diligence patterns, not specific engagements.<\/p>\n\n\n\n

Scenario 1: Same Portfolio, Different Conclusions on Obviousness<\/h3>\n\n\n\n

An AI tool flags a potential obviousness issue under \u00a7103 for a key patent in a biologics portfolio.  The tool identifies three prior art references that, in combination, appear to teach or suggest the claimed invention.  On its face, the risk looks significant.<\/p>\n\n\n\n

One investor\u2019s diligence team takes the flag at face value, notes it as a material risk in the report, and discounts the portfolio\u2019s valuation accordingly.  The analysis stops at the surface: the references exist, the combination is plausible, and the tool scored the risk as elevated.<\/p>\n\n\n\n

A second investor\u2019s team goes deeper.  They evaluate whether a person of ordinary skill in the art would actually have been motivated to combine those references\u2014and whether there was a reasonable expectation of success in doing so, particularly in the unpredictable biological arts.  They examine the prosecution history and discover that the examiner raised a similar combination during examination but was ultimately persuaded by applicant\u2019s arguments and a declaration under 37 C.F.R. \u00a71.132 presenting unexpected results data.  They review the patent\u2019s continuation family and find that related claims were allowed over the same art without even requiring argument.  They consider whether post-filing clinical data further supports non-obviousness by demonstrating unpredictable superior efficacy.<\/p>\n\n\n\n

The dataset is identical.  The AI output is the same.  But the second team\u2019s analysis reflects an understanding of how \u00a7103 actually works in practice\u2014particularly in the life sciences, where the Federal Circuit has repeatedly emphasized that the unpredictability of biological systems cuts against a finding of obviousness.  That understanding cannot be automated.  It requires familiarity with the case law, the technology, and the way patent examiners and PTAB judges actually evaluate these arguments.<\/p>\n\n\n\n

Scenario 2: Coverage That Looks Strong\u2014but Lacks Enforcement Leverage<\/h3>\n\n\n\n

AI-powered claim mapping shows that a portfolio\u2019s claims cover the lead product\u2014the compound, the formulation, and the primary method of treatment.  On a coverage heat map, the portfolio looks robust.  An initial diligence summary might report that the product is \u201cwell protected.\u201d<\/p>\n\n\n\n

But a closer look at claim scope tells a different story.  The claims may be drafted narrowly\u2014limited to a specific salt form, a specific dosage range, or a specific patient subpopulation.  A competitor evaluating a design-around would likely find room to develop an alternative formulation or dosing regimen that avoids literal infringement.  And if the claims are narrow enough, even a doctrine of equivalents argument may be difficult to sustain, particularly if prosecution history estoppel limits the available range of equivalents.<\/p>\n\n\n\n

The question that AI mapping answers\u2014\u201cdo the claims cover the product?\u201d\u2014is important but insufficient.  The question that matters for deal valuation is whether the claims create meaningful enforcement leverage against competitors.  That requires evaluating claim breadth relative to foreseeable design-arounds, the strength of the prosecution history, the landscape of third-party patents that could give rise to counterclaims, and the practical economics of enforcement in the relevant jurisdiction.  A portfolio that covers the product but cannot realistically exclude competitors may be worth far less than one with fewer patents but broader, more defensible claims.<\/p>\n\n\n\n

Scenario 3: A Portfolio That Appears Thin\u2014but Has Strategic Depth<\/h3>\n\n\n\n

AI analysis of a small biotech\u2019s portfolio flags limited continuation depth\u2014only a few granted patents, a modest number of pending applications, and no apparent formulation or method-of-treatment family beyond the core composition claims.  On a quantitative basis, the portfolio looks thin relative to competitors in the same therapeutic space.<\/p>\n\n\n\n

However, a practitioner who digs into the pending applications may find something different.  A provisional filing with broad disclosure and multiple embodiments may support a range of continuation claims that have not yet been filed.  Pending applications under examination may still have significant claim amendment runway.  The patent term for key filings may extend well beyond the expected product lifecycle, and the company may have preserved the ability to file continuation applications that capture competitors\u2019 later-emerging formulations or combination therapies.<\/p>\n\n\n\n

In this scenario, what AI flagged as a weakness\u2014limited portfolio size\u2014is actually a function of strategic timing.  The company has chosen not to pursue certain claims yet, preserving flexibility rather than prematurely narrowing scope.  This is a nuance that AI tools, which tend to equate portfolio depth with quantity, systematically miss.  An experienced practitioner recognizes that in early-stage biotech, the quality of the underlying disclosure and the flexibility of the pending filing strategy are often more important than the current claim count.<\/p>\n\n\n\n

The Opinions Layer:  Where AI Helps\u2014and Where It Cannot<\/h3>\n\n\n\n

Patent opinions\u2014whether for freedom to operate, invalidity, or infringement\u2014follow a similar pattern.  AI tools have dramatically accelerated the research phase.  Prior art searches that once consumed days are now completed in minutes.  Claim charts can be auto-populated.  Prosecution history summaries are generated algorithmically.<\/p>\n\n\n\n

But the opinion itself\u2014the legal conclusion that a business relies on to make investment, launch, or licensing decisions\u2014still depends on layers of judgment that AI does not reach.  A freedom-to-operate analysis, for example, requires not just identifying potentially relevant patents but evaluating how claims would be construed in litigation, whether prosecution history estoppel narrows the effective claim scope, whether potential invalidity arguments have merit and could be relied upon, and how a reasonable opposing party would likely respond.  These are probabilistic assessments grounded in experience with how courts, examiners, and adversaries actually behave.<\/p>\n\n\n\n

Similarly, an invalidity opinion requires weighing the strength of prior art not just as a matter of what is technically disclosed, but as a matter of how a PTAB panel or district court judge would likely view the combination in light of the relevant legal standards.  Practitioners know that the same prior art combination can be devastating in one art unit and entirely unpersuasive in another, depending on the technical complexity, the credibility of expert testimony, and the specific panel or judge involved.<\/p>\n\n\n\n

AI is an extraordinary research accelerant.  But the professional judgment that transforms research into a reliable opinion\u2014one a client can act on with confidence\u2014remains irreducibly human.<\/p>\n\n\n\n

What This Means for Practitioners and Clients<\/h3>\n\n\n\n

The practical implication of this shift is significant for both patent practitioners and the clients who rely on them.<\/p>\n\n\n\n

For practitioners, the value proposition has changed.  The ability to efficiently spot issues\u2014once a hallmark of a strong diligence team\u2014is now table stakes.  Clients increasingly expect that AI-assisted diligence will surface the relevant risks quickly and comprehensively.  What clients are willing to pay a premium for is the interpretive layer: the ability to take a list of flagged risks and translate them into actionable strategic guidance.  Which risks are real, and which are theoretical?  Which can be mitigated through prosecution, licensing, or portfolio development?  How should a particular risk profile affect deal terms, valuation, or competitive positioning? <\/p>\n\n\n\n

For clients\u2014whether investors evaluating a target, companies assessing their own portfolios, or boards making strategic IP decisions\u2014the challenge is recognizing that AI-generated diligence reports are starting points, not conclusions.  A report that lists risks without contextualizing them is of limited value.  The critical question is always: what does this risk mean for our specific commercial and strategic objectives, and what can we do about it?<\/p>\n\n\n\n

Conclusion<\/h3>\n\n\n\n

In 2026, the ability to identify patent risk is no longer a competitive advantage.  AI has made issue spotting faster, more consistent, and more accessible than at any point in the history of patent practice.<\/p>\n\n\n\n

The advantage now lies in what happens after the issues are identified.  The practitioners and teams that create the most value are those who can move beyond the AI-generated output and apply the judgment\u2014legal, technical, and commercial\u2014that transforms raw data into strategic insight.<\/p>\n\n\n\n

That is where deals are shaped, risks are managed, and value is either captured or left on the table.<\/p>\n\n\n\n

Next in this series: Part 2 will examine how the same dynamic\u2014AI-driven efficiency meeting human judgment\u2014is reshaping patent prosecution strategies.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Part 1: Due Diligence and Opinions This is the first article in a four-part series examining how AI is reshaping patent strategy across the lifecycle of life sciences assets\u2014from diligence and prosecution to transactions and litigation\u2014and where human judgment continues to drive…<\/p>\n","protected":false},"author":7,"featured_media":952,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"categories":[264,2,20,85],"tags":[371,84,22],"class_list":["post-959","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence","category-business-law","category-intellectual-property","category-patents","tag-ai","tag-intellectual-property","tag-patents"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/posts\/959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/comments?post=959"}],"version-history":[{"count":0,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/posts\/959\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/media\/952"}],"wp:attachment":[{"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/media?parent=959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/categories?post=959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.apslaw.com\/its-your-business\/wp-json\/wp\/v2\/tags?post=959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}